GlassScriptPhysician profile
Thomas O Oei
NPI 1861468530
$8,652.48
in general payments reported to CMS, 2019-2025
27 companies · $2,285 in 2025
The $2,285 reported for 2025 was more than what 83% of Retina Specialist providers received nationally (typical 2025 total: $460).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $732 · 2020: $204 · 2021: $582 · 2022: $612 · 2023: $1,729 · 2024: $2,510 · 2025: $2,285.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,523.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,523.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $2,038.80 | 2021-2025 | Vabysmo, Lucentis, Susvimo |
| Regeneron Healthcare Solutions, INC. | $750.58 | 2019-2025 | Eylea Hd, Eylea |
| Carl Zeiss Meditec USA, INC. | $650.55 | 2021-2024 | Visumax |
| Astellas Pharma US INC | $568.04 | 2023-2025 | Izervay |
| Biotissue Holdings INC. | $545.39 | 2019-2025 | |
| Abbvie INC. | $508.94 | 2022-2025 | |
| Alcon Vision LLC | $436.06 | 2022-2025 | Rocklatan, Clareon, Tryptyr |
| Bausch & Lomb Americas INC. | $380.66 | 2023-2025 | Xiidra, Vyzulta, Miebo |
| Harrow Eye, LLC | $283.82 | 2024-2025 | Iheezo, Vevye |
| Amgen INC. | $275.82 | 2024-2025 | Tepezza |
| Oyster Point Pharma, INC. | $271.55 | 2023-2025 | Tyrvaya, Ryzumvi |
| Novartis Pharmaceuticals Corporation | $232.27 | 2019-2023 | |
| Heidelberg Engineering, INC. | $208.57 | 2019 | |
| Allergan, INC. | $168.59 | 2019-2021 | |
| Apellis Pharmaceuticals, INC. | $158.10 | 2023-2024 | Syfovre |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb, A Division of Bausch Health US, LLC | $153.63 | 2019-2021 | |
| Ani Pharmaceuticals, INC. | $142.34 | 2025 | Yutiq, Iluvien |
| Sight Sciences, INC. | $136.96 | 2025 | Omni Surgical System |
| Dompe US, INC. | $121.85 | 2024 | Oxervate |
| Alimera Sciences, INC. | $120.83 | 2020-2024 | Yutiq, Iluvien |
| Optovue, INC. | $120.14 | 2019 | |
| Genentech, INC. | $108.54 | 2025 | Vabysmo |
| Nova Eye, INC. | $105.12 | 2025 | |
| Biogen, INC. | $80.92 | 2022-2024 | Byooviz |
| Notal Vision, INC. | $49.20 | 2021 | |
| Thea Pharma INC. | $18.46 | 2025 | Iyuzeh |
| Carl Zeiss Meditec, INC. | $16.75 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Oei listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.